Added to YB: 2025-09-29
Pitch date: 2025-06-30
ACAD [neutral]
ACADIA Pharmaceuticals Inc.
-1.16%
current return
Author Info
No bio for this author
Company Info
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America.
Market Cap
$3.8B
Pitch Price
$21.57
Price Target
N/A
Dividend
N/A
EV/EBITDA
28.44
P/E
10.10
EV/Sales
2.74
Sector
Biotechnology
Category
growth
Alger Weatherbie Specialized Growth Fund Portfolio Holding: ACADIA Pharmaceuticals Inc.
ACAD (holding update): Q1 beat driven by Nuplazid seeing highest new patient starts since 2020. Daybue showing sequential patient growth after 2 quarters stability with strong retention. ~30% salesforce expansion completed Q1, accelerating community provider prescriptions. 67% of Rett syndrome patients untreated = significant long-term growth runway. 2025 guidance reaffirmed.
Read full article (1 min)